Lupus nephritis and the anti-phospholipid antibody syndrome in pregnancy

Kidney International

Volumn 58, Issue 5, 2000, Pages 2240-2254

  Singh, A K ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Fetal antigens; Human reproduction; Immune system and pregnancy; Maternal immune response; Systemic lupus erythematosus

Indexed keywords

FETAL ANTIGEN; PHOSPHOLIPID ANTIBODY;

ADULT; ANTIPHOSPHOLIPID SYNDROME; AUTOIMMUNE DISEASE; CASE REPORT; FEMALE; FETUS DEATH; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNE SYSTEM; LUPUS ERYTHEMATOSUS NEPHRITIS; NEPHROTIC SYNDROME; PRIORITY JOURNAL; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS;

EID: 0033736303     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.2000.00399.x     Document Type: Review

References (92)

1. Quantitative analysis of peripheral blood Th0, Th1, Th2 and the TH1: Th2 cell ratio during normal human pregnancy and preeclampsia
2. Maternal cell-mediated immunity in pregnancy: Lymphocyte responses of mothers and their non-pregnant HLA identical sisters to paternal HLA
3. Suppressor T-lymphocytes in pregnancy
4. The immunological pregnancy protective effect of progesterone is manifested via controlling cytokine production
5. The expression of a progesterone-induced immunomodulatory protein in pregnancy lymphocytes
6. The alloantibody response of pregnant women and its suppression by soluble HLA antigens and anti-idiotypes antibodies
7. Idiotypic network regulations of immune responses to HLA
8. Maternal-fetal disparity in HLA class II alloantigens and the pregnancy-induced amelioration of rheumatoid arthritis
9. Immunologic response in pregnancy: Its role in endocrine disorders of pregnancy and influence on the course of maternal autoimmune diseases
10. Pregnancy associated depression of cell mediated immunity
11. Lupus pregnancy
12. Pregnancy among patients with systemic lupus erythematosus receiving immunosuppressive therapy
13. HLA and maternal-fetal recognition
14. Immunotolerant functions of HLA-G
15. The immunology of pregnancy
16. Cytokines considered critical in pregnancy
17. Regulation of the expression of autoimmunity in NZBxNZW F1 mice by sex hormones
18. Hormone replacement therapy in postmenopausal women with systemic lupus erythematosus
19. Placental transmission of lupus erythematosus factor
20. Systemic lupus erythematosus: Management during pregnancy
21. Problems associated with the management of pregnancies in patients with systemic lupus erythematosus
22. Systemic lupus erythematosus in pregnancy
23. Lupus nephropathy and pregnancy
24. Frequency of lupus flare in pregnancy: The Hopkins Lupus Pregnancy Center experience
25. Definition, incidence and clinical description of flare in systemic lupus erythematosus: A prospective cohort study
26. Systemic lupus erythematosus and pregnancy
27. Prospective study of pregnancy in systemic lupus erythematosus: Results of multidisciplinary approach
28. Obstetrical outcome in pregnancy in patients with systemic lupus erythematosus: A study of 60 Cases
29. Sterility and fertility rates, fetal wastage and maternal morbidity in systemic lupus erythematosus
30. Effect of pregnancy in patients with lupus nephropathy
31. Lupus and pregnancy studies
32. Pregnancy in lupus nephritis and related disorders
33. Systemic lupus erythematosus and pregnancy
34. The complement system in pregnancy
35. Activation of the complement pathway: Comparison of normal pregnancy, preeclampsia, and systemic lupus erythematosus during pregnancy
36. Outcome of pregnancy in patients with systemic lupus erythematosus: A prospective study
37. Lupus nephropathy and pregnancy: A study of 26 pregnancies in patients with systemic lupus erythematosus and nephritis
38. Evaluation of preterm delivery in a systemic lupus erythematosus pregnancy clinic
39. Systemic lupus erythematosus and pregnancy
40. Pregnancy course and complications in patients with systemic lupus erythematosus
41. Neonatal lupus risk to newborns of mothers with systemic lupus erythematosus
42. Possible discoid lupus erythematosus in newborn infant
43. Neonatal lupus syndromes
44. Congenital nephrotic syndrome in neonatal lupus syndrome
45. Neonatal lupus erythematosus simulating transient myasthenia gravis at presentation
46. Congenital heart block and associated cardiac pathology in neonatal lupus syndrome
47. Identification of mothers at risk for congenital heart block and other neonatal lupus syndromes in their children: Comparison of enzyme-linked immunosorbent assay and immunoblot for measurement of anti-SS-A/Ro and anti-SS-B/La antibodies
48. Connective-tissue disease, antibodies to ribonucleoprotein, and congenital heart block
49. Ro (SS-A) and anti-Ro (SS-A): An update
50. Autoantibody responses to the 'native' 52-kDa SS-A/Ro protein in neonatal lupus syndromes, systemic lupus erythematosus, and Sjogren's syndrome
51. Defining a novel 75-kDa phosphoprotein associated with SS-A/Ro and identification of distinct human autoantibodies
52. Heterogeneity of the anti-Ro (SSA) response in rheumatic diseases
53. Subclass distribution of maternal and neonatal anti-Ro (SSA) and La (SSB) antibodies in congenital heart block
54. Neonatal lupus syndromes
55. Obstetric complications associated with the lupus anticoagulant
56. Lupus anticoagulant in pregnancy
57. Thrombosis, abortion, cerebral disease and lupus anticoagulant
58. Comparison of the primary and secondary antiphospholipid syndrome: A European Multicenter Study of 114 patients
59. Specific antiphospholipid antibodies as a predictive variable in patients with recurrent pregnancy loss
60. Isotype distribution and clinical relevance of anti-beta2-glycoprotein I (beta2-GPI) antibodies: Importance of IgA isotype
61. IgA anticardiolipin and anti-beta2-glycoprotein I are the most prevalent isotypes in African American patients with systemic lupus erythematosus
62. Distribution of lupus anticoagulant and anticardiolipin antibody isotypes in a population with antiphospholipid syndrome
63. Anti-idiotype immunodulation of experimental anti-phospholipid syndrome via effect on Th1/Th2 expression
64. Antiphospholipid antibodies in obstetrics: New complexities and sites of action
65. Antiphospholipid antibodies from antiphospholipid syndrome patients activate endothelial cells in vitro and in vivo
66. A monoclonal IgG anticardiolipin antibody from a patient with the antiphospholipid syndrome is thrombogenic in mice
67. Factor V Leiden, antiphospholipid antibodies and thrombosis in systemic lupus erythematosus
68. Antibody-mediated disruption of the annexin-V antithrombotic shield: A new mechanism for thrombosis in the antiphospholipid syndrome
69. Thrombogenic properties of antiphospholipid antibodies do not depend on their binding to beta2 glycoprotein1 (beta2GP1) alone
70. Displacement of factor Va by annexin V
71. Reduction of annexin-V (placental anticoagulant protein-I) on placental villi of women with antiphospholipid antibodies and recurrent spontaneous abortion
72. Pregnancy loss in the antiphospholipid-antibody syndrome: A possible thrombogenic mechanism
73. Antiphospholipid antibodies in an in vivo thrombosis model in mice
74. The management of thrombosis in the antiphospholipid-antibody syndrome
75. Randomized controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies
76. A clinical trial for the treatment of antiphospholipid antibody-associated recurrent pregnancy loss with lower dose heparin and aspirin
77. Pregnancy complications in women with recurrent miscarriage associated with antiphospholipid antibodies treated with low dose aspirin and heparin
78. Prednisone and aspirin in women with autoantibodies and unexplained recurrent fetal loss
79. Induction of experimental antiphospholipid antibody syndrome in PL/J mice following immunization with beta 2 GPI
80. The pathogenic role of anti-phosphatidylserine antibodies: Active immunization with the antibodies leads to the induction of antiphospholipid syndrome
81. Antiphospholipid syndrome and the idiotypic network
82. Weekly clinicopathological exercises. Case 18-19999: A 54-year-old woman with acute renal failure and thrombocytoecnia
83. The intrarenal vascular lesions associated with primary antiphospholipid syndrome
84. Annexin-V: Crystal structure and its implications on function
85. Reduction of annexin-V (placental anticoagulant protein-I) on placental villi of women with antiphospholipid antibodies and recurrent spontaneous abortion
86. Pregnancy loss in the antiphospholipid-antibody syndrome: A possible thrombogenic mechanism
87. Antiphospholipid antibodies from antiphospholipid syndrome patients activate endothelial cells in vitro and in vivo
88. A clinical trial for the treatment of antiphospholipid antibody-associated recurrent pregnancy loss with lower dose heparin and aspirin
89. Antiphospholipid antibody-associated recurrent pregnancy loss: Treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone
90. Outcome of pregnancy in women with moderate or severe renal insufficiency
91. Do low-risk pregnant women with antiphospholipid antibodies need to be treated? Organizing Group of the Antiphospholipid Antibody Treatment Trial
92. Placental pathology in antiphospholipid syndrome